Summit X LLC trimmed its position in shares of Celgene Co. (NASDAQ:CELG) by 22.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,288 shares of the biopharmaceutical company’s stock after selling 955 shares during the quarter. Summit X LLC’s holdings in Celgene were worth $477,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Neuberger Berman Group LLC increased its holdings in Celgene by 4.0% in the 1st quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock worth $229,553,000 after acquiring an additional 71,729 shares in the last quarter. Grisanti Capital Management LLC purchased a new stake in Celgene in the 2nd quarter worth $3,616,000. Lincoln Capital Corp increased its holdings in Celgene by 0.6% in the 2nd quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock worth $3,971,000 after acquiring an additional 185 shares in the last quarter. RiverPoint Capital Management LLC increased its holdings in Celgene by 3.1% in the 2nd quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock worth $15,799,000 after acquiring an additional 3,680 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in Celgene by 9.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock worth $83,344,000 after acquiring an additional 54,210 shares in the last quarter. 79.84% of the stock is owned by hedge funds and other institutional investors.

Celgene Co. (CELG) opened at $108.04 on Tuesday. Celgene Co. has a 1 year low of $94.55 and a 1 year high of $147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. The company has a market cap of $86,140.35, a PE ratio of 17.09, a price-to-earnings-growth ratio of 0.84 and a beta of 1.78.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The company had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter in the prior year, the company posted $1.58 earnings per share. Celgene’s revenue for the quarter was up 10.2% compared to the same quarter last year. equities research analysts forecast that Celgene Co. will post 6.68 EPS for the current fiscal year.

CELG has been the topic of several recent research reports. Morgan Stanley cut shares of Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 target price on the stock. in a research note on Thursday, October 5th. BTIG Research reaffirmed a “hold” rating on shares of Celgene in a research note on Sunday, October 22nd. Cantor Fitzgerald reaffirmed a “hold” rating and set a $112.00 target price on shares of Celgene in a research note on Monday, October 30th. Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 target price on the stock in a research note on Monday, October 23rd. Finally, Oppenheimer set a $166.00 target price on shares of Celgene and gave the stock a “buy” rating in a research note on Thursday, November 16th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the company. Celgene presently has a consensus rating of “Buy” and a consensus target price of $136.21.

In other Celgene news, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now owns 3,925 shares of the company’s stock, valued at $564,768.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.95% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Summit X LLC Sells 955 Shares of Celgene Co. (CELG)” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/summit-x-llc-sells-955-shares-of-celgene-co-celg/1772769.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.